Based in Menlo Park, California and incorporated in the state of Delaware in June, 2002, Xtent, Inc. is a development stage medical device company focused on developing and commercializing its proprietary Custom NX drug eluting stent (DES) Systems to treat coronary artery disease (CAD). The company primarily focuses on its development efforts to create Custom NX DES Systems, which allow a physician to deploy single or multiple stents of customizable lengths with a single device. Xtent's stent systems include the Custom NX 36 which is used to treat single or multiple lesions and the Custom NX 60 that is used to treat one long lesion or multiple smaller lesions with the use of one device. Currently, the company has 108 employees. In May 2004, the company entered into a license agreement with Biosensors International Group Ltd. and Biosensors Europe S.A., obtaining worldwide non-exclusive rights to use Biosensors' drug coating on its products.
On February 1, 2007, Xtent completed its 4.7 million common share initial public offering, raising net proceeds of approximately $68.2 million.